ADCs and Novel Drug Conjugates in Asia Report
Dive into an insightful analysis of the ADC commercial landscape in Asia. Curated by our expert Beacon Research Team, this report unveils invaluable competitive intelligence that will fuel your strategic decision-making.
What’s inside the report?
- Insights into the Asian ADC market over the past 10 years.
- Detailed company profiles of key players such as Lego Chem Biosciences and MediLink Therapeutics.
- The top 10 drug conjugate deals of 2023.
- An exploration of the prevalent drug targets shaping the landscape.
- An overview of deal types, highlighting the shift observed between 2022 and 2023.
- Insights into financing trends across various drug modalities.
You May Also Be Interested In…
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
